骨转换标记物与2型糖尿病微血管并发症的关系

承德医学院学报 ›› 2019, Vol. 36 ›› Issue (3): 198-201.

骨转换标记物与2型糖尿病微血管并发症的关系

刘雨轩, 刘晓燕^△, 高宇, 孙志新

承德医学院附属医院内分泌科,河北承德 067000

收稿日期:2019-01-31 出版日期:2019-06-10 发布日期:2021-11-18
通讯作者: △

RELATIONSHIPS BETWEEN BONE TURNOVER MARKERS AND DIABETIC MICROVASCULAR COMPLICATIONS IN TYPE 2 DIABETES MELLITUS

LIU Yu-xuan, LIU Xiao-yan, GAO Yu, et al

Department of Endocrinology, the Affiliated Hospital of Chengde Medical College, Hebei Chengde 67000, China

Received:2019-01-31 Online:2019-06-10 Published:2021-11-18

摘要/Abstract

摘要： 目的:探讨骨转换标志物与2型糖尿病合并微血管并发症的关系。方法:146例2型糖尿病患者根据是否合并糖尿病微血管并发症分为实验组和对照组,实验组77例患者,合并糖尿病肾病和/或糖尿病视网膜病变,对照组69例患者,未合并糖尿病肾病和/或糖尿病视网膜病变。分别记录两组患者的一般资料,检测两组患者的血生化指标和骨转换标志物。结果:实验组患者的病程明显长于对照组（P<0.05）;实验组患者血清羧基末端胶原交联肽（CTX）明显高于对照组,骨钙素（OC）明显低于对照组（P<0.05）。Logistic回归分析显示,CTX、病程是2型糖尿病合并微血管病变的危险因素,OC是2型糖尿病合并微血管病变的保护因素。结论:骨转换标记物CTX、OC与2型糖尿病患者微血管并发症发生风险有关,二者有望成为监测2型糖尿病患者微血管病变及骨代谢变化的标记物。

关键词: 2型糖尿病, 糖尿病微血管并发症, 骨转换标志物, 羧基末端胶原交联肽（CTX）, 骨钙素（OC）

Abstract: Objective: To investigate the relationships between bone turnover markers and diabetic microvascular complications in type 2 diabetes mellitus. Methods: 146 type 2 diabetes mellitus patients were divided into experimental group (77 patients, complicated with diabetic nephropathy and/or diabetic retinopathy) and control group (69 patients, no diabetic microvascular complications). The general informations of patients in 2 groups were recorded; and the blood biochemical indicators and bone turnover markers of patients were detected. Results: The course of disease of patients in experimental group was remarkably longer than control group (P<0.05); the carboxy-terminal collagen crosslinks (CTX) of patients in experimental group was remarkably higher than control group, the osteocalcin (OC) was remarkably lower (P<0.05). Logistic regression analysis showed that CTX and course of disease were risk factors of type 2 diabetes mellitus with microangiopathy, OC was protective factor. Conclusions: Bone turnover markers CTX and OC are associated with the risk of microvascular complications in patients with type 2 diabetes mellitus, which are expected to be markers for monitoring microangiopathy and bone metabolism in patients with type 2 diabetes mellitus.

Key words: Tyep 2 diabetes mellitus, Diabetic microvascular complications, Bone turnover markers, Carboxy-terminal collagen crosslinks (CTX), Osteocalcin (OC)

中图分类号:

R587.1

刘雨轩, 刘晓燕, 高宇, 孙志新. 骨转换标记物与2型糖尿病微血管并发症的关系[J]. 承德医学院学报, 2019, 36(3): 198-201.

LIU Yu-xuan, LIU Xiao-yan, GAO Yu, et al. RELATIONSHIPS BETWEEN BONE TURNOVER MARKERS AND DIABETIC MICROVASCULAR COMPLICATIONS IN TYPE 2 DIABETES MELLITUS[J]. Journal of Chengde Medical University, 2019, 36(3): 198-201.

参考文献

[1] JOHNELL O, KANIS JA.An estimate of the worldwide prevalence and disability associated with osteoporotic fractures[J]. Osteoporos Int, 2006, 17(12): 1726-1733.
[2] DEDE A D, TOURNIS S, DONTAS I, et al.Type 2 diabetes mellitus and fracture risk[J]. Metabolism, 2014, 63(12): 1480-1490.
[3] YOSHIMURA N, MURAKI S, OKA H, et al.Biochemical markers of bone turnover as predictors of osteoporosis and osteoporotic fractures in men and women: 10-year follow-up of the Taiji cohort[J]. Mod Rheumatol, 2011, 21(6): 608-620.
[4] STARUP-LINDE J, VESTERGAARD P.Biochemical bone turnover markers in diabetes mellitus - A systematic review[J]. Bone, 2016, 82: 69-78.
[5] THRAILKILL K M, LIU L, WAHL E C, et al.Bone formation is impaired in a model of type 1 diabetes[J]. Diabetes, 2005, 54(10): 2875-2881.
[6] LERCHBAUM E, SCHWETZ V, NAUCK M, et al.Lower bone turnover markers in metabolic syndrome and diabetes: the population-based Study of Health in Pomerania[J]. Nutr Metab Cardiovasc Dis, 2015, 25(5): 458-463.
[7] TURNER R T, KALRA S P, WONG C P, et al.Peripheral leptin regulates bone formation[J]. J Bone Miner Res, 2013, 28(1): 22-34.
[8] LIN X, BRENNAN-SPERANZA T C, LEVINGER I, et al. Undercarboxylated Osteocalcin: Experimental and Human Evidence for a Role in Glucose Homeostasis and Muscle Regulation of Insulin Sensitivity[J]. Nutrients, 2018, 10(7): pii: E847.
[9] GUPTE A A, SABEK O M, FRAGA D, et al.Osteocalcin Protects Against Nonalcoholic Steatohepatitis in a Mouse Model of Metabolic Syndrome[J]. Endocrinology, 2014, 155(12): 4697-4705.
[10] MARX R E, CILLO JE JR., ULLOA J J.Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment[J]. J Oral Maxillofac Surg, 2007, 65(12):2397-2410.
[11] ROSEN H N, MOSES A C, GARBER J, et al.Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy[J]. Calcif Tissue Int, 2000, 66(2): 100-103.
[12] ZOCH M L, CLEMENS T L, RIDDLE R C.New insights into the biology of osteocalcin[J]. Bone, 2016, 82: 42-49.